Enrolling Studies:

• A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (microbiota suspension) in Subjects with Recurrent Clostridium difficile Infection
• A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium Difficile Infection

Enrollment Closed:

• A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Rebiotix RBX2660 (microbiota suspension) for the Prevention of Recurrent Clostridium difficile Infection

Recently Completed:

• A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid versus Vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD)
• An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (microbiota suspension) for the Treatment of Recurrent Clostridium difficile Infection